Do not stop Namenda (memantine) without first asking the prescriber to plan and monitor a withdrawal trial. Ask why it was prescribed, whether it still provides meaningful benefit, and how the dose should be reduced. Namenda is a medicine used for dementia symptoms, not a cure for dementia. Because evidence on stopping memantine alone is limited, the decision should reflect the person's diagnosis, treatment goals, side effects, kidney function, and recent changes.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What condition and goal are being treated?
- Could side effects or drug levels explain the concern?
- When is a withdrawal trial reasonable?
- What should the stopping and monitoring plan include?
What condition and goal are being treated?
Start by confirming the dementia diagnosis and the original reason for treatment. The U.S. DailyMed label specifies memantine for moderate-to-severe dementia of the Alzheimer's type; use for another dementia falls outside that specific indication described in the FDA labeling.
Ask the prescriber to identify the intended benefit. Was the goal to preserve thinking, daily function, behavior, quality of life, or some combination? A clear target gives the family and clinician something concrete to assess during a withdrawal trial. Useful questions include:.
- What diagnosis is Namenda treating?
- What benefit was expected when it began?
- Was any benefit documented?
- Which current abilities or behaviors might change if it is stopped?
- Does the present treatment goal still fit the person's stage of dementia?
Could side effects or drug levels explain the concern?
Describe the specific problem rather than simply saying the medicine "is not helping." Note when confusion, dizziness, headaches, constipation, or functional changes appeared and whether they vary during the day. DailyMed lists dizziness, headache, confusion, and constipation among common adverse reactions.
The label also recommends a reduced dose for severe kidney impairment and notes that alkaline urine can slow elimination and raise memantine levels according to its dosing and safety information. Ask the prescriber to review:.
- Current kidney function
- The dose being taken
- Prescription and nonprescription medicines
- Whether a recent symptom fits a known adverse reaction
- Whether adjusting the dose should be considered before stopping
When is a withdrawal trial reasonable?
A deprescribing guideline recommends considering a trial after more than 12 months of treatment when cognition or function has worsened, no benefit was ever observed, or dementia has become severe or end-stage. It applies that recommendation to memantine use in Alzheimer's disease, Parkinson's disease dementia, and Lewy body dementia in its deprescribing guidance. These conditions make a trial reasonable; they do not prove that stopping will help.
Three of eight nonrandomized discontinuation studies reported more symptom recurrence after memantine stopped, while the studies found no consistent differences in cognition, function, global change, or neuropsychiatric scores. The evidence has an important gap. A 2021 Cochrane review found no randomized trial specifically studying withdrawal of memantine alone, so it could not establish the effects of stopping namenda by itself from randomized evidence.
What should the stopping and monitoring plan include?
The deprescribing guideline advises stepping down through available doses or halving the dose about every four weeks before stopping. Ask for a written schedule rather than treating discontinuation as a one-time, unmonitored event. Before the first reduction, record a simple baseline: The clinician and caregiver should reassess cognition, daily function, behavior, and quality of life about every four weeks.
Agree in advance on who will observe changes, when to contact the prescriber, and what would count as clear worsening. If decline appears during the trial, the guideline recommends first checking for another cause, including infection or dehydration-related delirium. If the decline is attributable to withdrawal, the plan should allow the prescriber to restart memantine.
- Ability to complete familiar daily tasks
- Memory and communication
- Agitation, distress, or other behavior
- Overall quality of life
- The observations most important to the person and caregiver
